Amorphical has completed patient enrolment in a Phase 2 trial [...]

Medicus Pharma has received FDA clearance to begin a Phase [...]

CAMP4 Therapeutics has received Australian regulatory and ethics clearance to [...]

The EMA’s CHMP has recommended approval of NEZGLYAL for boys [...]

Skyhawk Therapeutics has expanded its global pivotal Phase 2/3 clinical [...]

Grifols has dosed the first participant in a Phase 3 [...]

Elixirgen Therapeutics has signed an option agreement with Nippon Shinyaku [...]

Cereno Scientific has reported encouraging 12-month safety and clinical observations [...]

The European Commission has granted orphan drug designation to Chiesi [...]

Grifols has launched Fesilty in the USA, making the fibrinogen [...]